Trevi Therapeutics (TRVI) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

TRVI Stock Forecast

Trevi Therapeutics stock forecast is as follows: an average price target of $8.00 (represents a 193.04% upside from TRVI’s last price of $2.73) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

TRVI Price Target

The average price target for Trevi Therapeutics (TRVI) is $8.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $6.00. This represents a potential 193.04% upside from TRVI's last price of $2.73.

TRVI Analyst Ratings

Buy

According to 6 Wall Street analysts, Trevi Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for TRVI stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Trevi Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 22, 2024	Oren Livnat	H.C. Wainwright	-	-	79.10%	119.78%
Oct 04, 2024	Mayank Mamtani	B.Riley Financial	-	-	98.68%	119.78%
Jul 09, 2022	Leland Gershall	Oppenheimer	-	-	203.80%	339.56%

Row per page

Go to

The latest Trevi Therapeutics stock forecast, released on Oct 22, 2024 by Oren Livnat from H.C. Wainwright, set a price target of $6.00, which represents a 79.10% increase from the stock price at the time of the forecast ($3.35), and a 119.78% increase from TRVI last price ($2.73).

Trevi Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	1	2	2
Avg Price Target	$6.00	$6.00	$6.00
Last Closing Price	$2.73	$2.73	$2.73
Upside/Downside	119.78%	119.78%	119.78%

In the current month, the average price target of Trevi Therapeutics stock is $6.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 119.78% increase as opposed to Trevi Therapeutics's last price of $2.73. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 22, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 30, 2024	Raymond James		Outperform	Initialise
Aug 30, 2024	H.C. Wainwright		Buy	Initialise
Aug 19, 2024	EF Hutton		Buy	Initialise
Jun 12, 2024	Rodman & Renshaw		Buy	Initialise
Nov 11, 2022	Needham	Buy	Buy	Hold
Jun 30, 2022	Oppenheimer	Outperform	Outperform	Hold
Jun 29, 2022	Needham	Buy	Buy	Hold
May 25, 2022	Oppenheimer		Outperform	Initialise

Row per page

Go to

Trevi Therapeutics's last stock rating was published by H.C. Wainwright on Oct 22, 2024. The company gave TRVI a "Buy" rating, the same as its previous rate.

Trevi Therapeutics Financial Forecast

Trevi Therapeutics Revenue Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$67.56M	$63.74M	$62.46M	$61.19M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
High Forecast	$67.56M	$63.74M	$62.46M	$61.19M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	$67.56M	$63.74M	$62.46M	$61.19M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
# Analysts	1	1	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Trevi Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. TRVI's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Trevi Therapeutics EBITDA Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

undefined analysts predict TRVI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Trevi Therapeutics's previous annual EBITDA (undefined) of $NaN.

Trevi Therapeutics Net Income Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$32.01M	$30.75M	$30.69M	$30.11M	$-5.08M	$-4.59M	$-4.25M	$-4.49M	$-7.13M	$-6.43M	$-5.97M	$-6.29M	$-12.76M	$-11.56M	$-11.77M	$-11.69M	$-12.47M	$-12.08M	$-10.97M
High Forecast	$32.01M	$30.75M	$30.69M	$30.11M	$-5.08M	$-4.59M	$-4.25M	$-4.49M	$-7.13M	$-6.43M	$-5.97M	$-6.29M	$-12.76M	$-11.56M	$-11.77M	$-10.71M	$-11.43M	$-12.08M	$-10.97M
Low Forecast	$32.01M	$30.75M	$30.69M	$30.11M	$-5.08M	$-4.59M	$-4.25M	$-4.49M	$-7.13M	$-6.43M	$-5.97M	$-6.29M	$-12.76M	$-11.56M	$-11.77M	$-13.64M	$-13.51M	$-12.08M	$-10.97M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Trevi Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TRVI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Trevi Therapeutics SG&A Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Trevi Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to TRVI last annual SG&A of $NaN (undefined).

Trevi Therapeutics EPS Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$0.32	$0.30	$0.30	$0.30	$-0.05	$-0.05	$-0.04	$-0.04	$-0.07	$-0.06	$-0.06	$-0.06	$-0.13	$-0.11	$-0.12	$-0.12	$-0.12	$-0.12	$-0.11
High Forecast	$0.32	$0.30	$0.30	$0.30	$-0.05	$-0.05	$-0.04	$-0.04	$-0.07	$-0.06	$-0.06	$-0.06	$-0.13	$-0.11	$-0.12	$-0.11	$-0.11	$-0.12	$-0.11
Low Forecast	$0.32	$0.30	$0.30	$0.30	$-0.05	$-0.05	$-0.04	$-0.04	$-0.07	$-0.06	$-0.06	$-0.06	$-0.13	$-0.11	$-0.12	$-0.13	$-0.13	$-0.12	$-0.11
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

According to undefined Wall Street analysts, Trevi Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TRVI previous annual EPS of $NaN (undefined).

Trevi Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
SQZ	SQZ Bio	-	-	90809.09%	Buy
SPRO	Spero Therapeutics	-	-	740.34%	Buy
CHRS	Coherus BioSciences	-	-	718.18%	Hold
ANTX	AN2 Therapeutics	-	-	611.38%	Buy
PRLD	Prelude Therapeutics	-	-	544.33%	Sell
LIFE	aTyr Pharma	-	-	478.95%	Buy
CUE	Cue Biopharma	-	-	320.39%	Buy
ANEB	Anebulo Pharmaceuticals	-	-	300.00%	Buy
BCAB	BioAtla	-	-	259.71%	Buy
CCCC	C4 Therapeutics	-	-	236.66%	Buy
TRVI	Trevi Therapeutics	-	-	193.04%	Buy
RZLT	Rezolute	-	-	177.78%	Buy
LYRA	Lyra Therapeutics	-	-	177.78%	Hold
CGEM	Cullinan Oncology	-	-	157.77%	Buy
FHTX	Foghorn Therapeutics	-	-	111.53%	Buy
ORIC	ORIC Pharmaceuticals	-	-	86.40%	Buy
BOLT	Bolt Biotherapeutics	-	-	75.44%	Hold
CYT	Cyteir Therapeutics	-	-	-33.77%	Sell
GRCL	Gracell Bio	-	-	-41.46%	Buy

TRVI Forecast FAQ

Is Trevi Therapeutics a good buy?

Yes, according to 6 Wall Street analysts, Trevi Therapeutics (TRVI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of TRVI's total ratings.

What is TRVI's price target?

Trevi Therapeutics (TRVI) average price target is $8 with a range of $6 to $12, implying a 193.04% from its last price of $2.73. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Trevi Therapeutics stock go up soon?

According to Wall Street analysts' prediction for TRVI stock, the company can go up by 193.04% (from the last price of $2.73 to the average price target of $8), up by 339.56% based on the highest stock price target, and up by 119.78% based on the lowest stock price target.

Can Trevi Therapeutics stock reach $4?

TRVI's average twelve months analyst stock price target of $8 supports the claim that Trevi Therapeutics can reach $4 in the near future.

What is Trevi Therapeutics's current price target trend?

1 Wall Street analyst forecast a $6 price target for Trevi Therapeutics (TRVI) this month, up 119.78% from its last price of $2.73. Compared to the last 3 and 12 months, the average price target increased by 119.78% and increased by 119.78%, respectively.

What are Trevi Therapeutics's analysts' financial forecasts?

Trevi Therapeutics's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-18.41M (high $-18.41M, low $-18.41M), average SG&A $0 (high $0, low $0), and average EPS is $-0.182 (high $-0.182, low $-0.182). TRVI's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $254.95M (high $254.95M, low $254.95M), average EBITDA is $0 (high $0, low $0), average net income is $123.55M (high $123.55M, low $123.55M), average SG&A $0 (high $0, low $0), and average EPS is $1.22 (high $1.22, low $1.22).